UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Diabetes provides an unfavorable environment for muscle mass and function after muscle injury in mice

Pathobiology (Basel), 2007-01, Vol.74 (5), p.291-300

2007

Volltextzugriff (PDF)

Myostatin inhibition for neuromuscular disorders: defining the good candidate

Neuromuscular disorders : NMD, 2017-03, Vol.27, p.S8-S8

2017

Volltextzugriff (PDF)

Correlation between low FAT1 expression and early affected muscle in FSHD

Neuromuscular disorders : NMD, 2015-10, Vol.25, p.S312-S312

2015

Volltextzugriff (PDF)

Muscle weakness and atrophy are associated with decreased regenerative capacity and changes in mTOR signaling in skeletal muscles of venerable (18-24-month-old) dystrophic mdx mice

Muscle & nerve, 2010-06, Vol.41 (6), p.809-818

2010

Volltextzugriff (PDF)

La complémentation en citrulline améliore la performance physique au cours de l’exercice

Nutrition clinique et métabolisme, 2016-06, Vol.30 (2), p.120-120

2016

Volltextzugriff (PDF)

The beneficial effect of myostatin deficiency on maximal muscle force and power is attenuated with age

Experimental gerontology, 2013-02, Vol.48 (2), p.183-190

2013

Volltextzugriff (PDF)

Functional, cellular and molecular aspects of skeletal muscle recovery after injury induced by snake venom from Notechis scutatus scutatus

Toxicon (Oxford), 2005-05, Vol.45 (6), p.789-801

2005

Volltextzugriff (PDF)

Androgen replacement therapy improves function in male rat muscles independently of hypertrophy and activation of the Akt/mTOR pathway

Acta Physiologica, 2009-04, Vol.195 (4), p.471-482

2009

Volltextzugriff (PDF)

P3.25 Satellite cell dependent growth and regeneration of skeletal muscle requires BMP signalling

Neuromuscular disorders : NMD, 2010-10, Vol.20 (9), p.648-648

2010

Volltextzugriff (PDF)

Differential recovery of neuromuscular function after nerve/muscle injury induced by crude venom from Notechis scutatus, cardiotoxin from Naja atra and bupivacaine treatments in mice

Neuroscience research, 2007-07, Vol.58 (3), p.317-323

2007

Volltextzugriff (PDF)

G.P.8.07 Increased oxidative metabolism in mdx muscle treated by a combination of exon skipping and myostatin blockade

Neuromuscular disorders : NMD, 2008-10, Vol.18 (9), p.783-784

2008

Volltextzugriff (PDF)

NEW THERAPEUTIC APPROACHES AND THEIR READOUT: O.16Myostatin expression is a reliable and quantifiable biomarker to monitor dose-dependent drug response in muscular dystrophy

Neuromuscular disorders : NMD, 2018-10, Vol.28, p.S91-S91

2018

Volltextzugriff (PDF)

NEW THERAPEUTIC APPROACHES AND THEIR READOUT

Neuromuscular disorders : NMD, 2018-10, Vol.28, p.S91

2018

Volltextzugriff (PDF)

G.P.1.10 DHPR α1 S subunit controls skeletal muscle mass and morphogenesis

Neuromuscular disorders : NMD, 2009-09, Vol.19 (8), p.559-559

2009

Volltextzugriff (PDF)

Myostatin expression in neuromuscular diseases

Neuromuscular disorders : NMD, 2018-04, Vol.28, p.S2

2018

Volltextzugriff (PDF)

Myostatin is a reliable biomarker for monitoring drug response in DMD

Neuromuscular disorders : NMD, 2018-04, Vol.28, p.S19

2018

Volltextzugriff (PDF)

S05 - Myostatin expression in neuromuscular diseases

Neuromuscular disorders : NMD, 2018-04, Vol.28, p.S2-S2

2018

Volltextzugriff (PDF)

D42 - Myostatin is a reliable biomarker for monitoring drug response in DMD

Neuromuscular disorders : NMD, 2018-04, Vol.28, p.S19-S19

2018

Volltextzugriff (PDF)

Facteurs mécaniques de la performance lors de la phase d'accélération en BMX chez des pilotes entraînés

Science & sports, 2007-06, Vol.22 (3), p.179-181

2007

Volltextzugriff (PDF)

Influence de variables psychologiques sur la performance au test de Wingate chez des pilotes de BMX

Science & sports, 2006-10, Vol.21 (5), p.297-299

2006

Volltextzugriff (PDF)

Impaired skeletal muscle repair after ischemia-reperfusion injury in mice

BioMed research international, 2010-01, Vol.2010, p.724914-10

2010

Volltextzugriff (PDF)

Myostatin expression levels in neuromuscular diseases participates in anti-myostatin clinical failure

Neuromuscular disorders : NMD, 2017-10, Vol.27, p.S231

2017

Volltextzugriff (PDF)

EC.O.4 - Reversible endogenous downregulation of myostatin pathway in wasting neuromuscular diseases explains challenges of anti-myostatin therapeutic approaches

Neuromuscular disorders : NMD, 2017-10, Vol.27, p.S97-S98

2017

Volltextzugriff (PDF)

Reversible endogenous downregulation of myostatin pathway in wasting neuromuscular diseases explains challenges of anti-myostatin therapeutic approaches

Neuromuscular disorders : NMD, 2017-10, Vol.27, p.S97-S98

2017

Volltextzugriff (PDF)

P.450 - Myostatin expression levels in neuromuscular diseases participates in anti-myostatin clinical failure

Neuromuscular disorders : NMD, 2017-10, Vol.27, p.S231-S231

2017

Volltextzugriff (PDF)

1 – 25 von 43

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(42)
Mit Volltextzugriff
(41)

Publikationsform

Artikel
(43)

Sprache

Englisch
(38)
Französisch
(5)

Erscheinungsjahr

n.n

Thema

Animals
(13)
Life Sciences & Biomedicine
(13)
Science & Technology
(13)
Mice
(11)
Neurology
(10)
Male
(9)
Muscle, Skeletal - Pathology
(8)
Muscle, Skeletal - Physiopathology
(7)
Life Sciences
(6)
Biological And Medical Sciences
(5)
Myosin Heavy Chains - Metabolism
(5)
Skeletal Muscle
(5)
Atrophy
(4)
Cellular Biology
(4)
Fundamental And Applied Biological Sciences. Psychology
(4)
Muscular Atrophy - Pathology
(4)
Muscular Atrophy - Physiopathology
(4)
Musculoskeletal System
(4)
Regeneration
(4)
Rodents
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Diabetes provides an unfavorable environment for muscle mass and function after muscle injury in mice

Myostatin inhibition for neuromuscular disorders: defining the good candidate

Correlation between low FAT1 expression and early affected muscle in FSHD

Muscle weakness and atrophy are associated with decreased regenerative capacity and changes in mTOR signaling in skeletal muscles of venerable (18-24-month-old) dystrophic mdx mice

La complémentation en citrulline améliore la performance physique au cours de l’exercice

The beneficial effect of myostatin deficiency on maximal muscle force and power is attenuated with age

Functional, cellular and molecular aspects of skeletal muscle recovery after injury induced by snake venom from Notechis scutatus scutatus

Androgen replacement therapy improves function in male rat muscles independently of hypertrophy and activation of the Akt/mTOR pathway

P3.25 Satellite cell dependent growth and regeneration of skeletal muscle requires BMP signalling

Differential recovery of neuromuscular function after nerve/muscle injury induced by crude venom from Notechis scutatus, cardiotoxin from Naja atra and bupivacaine treatments in mice

G.P.8.07 Increased oxidative metabolism in mdx muscle treated by a combination of exon skipping and myostatin blockade

NEW THERAPEUTIC APPROACHES AND THEIR READOUT: O.16Myostatin expression is a reliable and quantifiable biomarker to monitor dose-dependent drug response in muscular dystrophy

NEW THERAPEUTIC APPROACHES AND THEIR READOUT

G.P.1.10 DHPR α1 S subunit controls skeletal muscle mass and morphogenesis

Myostatin expression in neuromuscular diseases

Myostatin is a reliable biomarker for monitoring drug response in DMD

S05 - Myostatin expression in neuromuscular diseases

D42 - Myostatin is a reliable biomarker for monitoring drug response in DMD

Facteurs mécaniques de la performance lors de la phase d'accélération en BMX chez des pilotes entraînés

Influence de variables psychologiques sur la performance au test de Wingate chez des pilotes de BMX

Impaired skeletal muscle repair after ischemia-reperfusion injury in mice

Myostatin expression levels in neuromuscular diseases participates in anti-myostatin clinical failure

EC.O.4 - Reversible endogenous downregulation of myostatin pathway in wasting neuromuscular diseases explains challenges of anti-myostatin therapeutic approaches

Reversible endogenous downregulation of myostatin pathway in wasting neuromuscular diseases explains challenges of anti-myostatin therapeutic approaches

P.450 - Myostatin expression levels in neuromuscular diseases participates in anti-myostatin clinical failure

Suchergebnisse filtern